Global R&D Pipeline
My Favorite
Hot Targets:
TL1A
Back
Total number of drugs
51
Phase II and later clinical stages
11.8%
Involving companies
66
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESN-X | ESN-X | Small molecule drug | Immune System Diseases Digestive System Disorders | NLRP3 inhibitors TL1A inhibitors | Enveda Therapeutics, Inc. | Enveda Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | ESN-X | - | - | detail > | |
| HXN-1002 | HXN-1002 | Bispecific antibody | Immune System Diseases Digestive System Disorders | TL1A inhibitors α4β7 antagonists | Earendil Labs | Huashen Zhiyao Technology (Beijing) Co., Ltd. Earendil Labs | Preclinical | Preclinical | - | - | - | - | - | - | - | - | HXN-1002 | - | - | detail > | |
| SPY-230 | SPY-230 | Bispecific antibody | Immune System Diseases Digestive System Disorders | IL-23 inhibitors TL1A inhibitors | Spyre Therapeutics, Inc. | Spyre Therapeutics, Inc. Paragon Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | SPY-230 | - | - | detail > | |
| ESN-X1 | ESN-X1 | Small molecule drug | Digestive System Disorders | NLRP3 inhibitors TL1A inhibitors | Enveda Therapeutics, Inc. | Enveda Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | ESN-X1 | - | - | detail > | |
| TL1A x IL-23(Xencor) | TL1A x IL-23(Xencor) | Bispecific antibody | Immune System Diseases Digestive System Disorders | IL-23 modulators TL1A modulators | Xencor, Inc. | Xencor, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | TL1A x IL-23(Xencor) | - | - | detail > | |
| ES-302 | ES-302 | Bispecific antibody | Immune System Diseases Digestive System Disorders | IL-23p19 inhibitors TL1A inhibitors | Elpiscience Biopharma Ltd. | Elpiscience Biopharma Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | ES-302 | - | - | detail > | |
| ABS-101 (Absci) | ABS-101 (Absci) | Monoclonal antibody | Immune System Diseases Digestive System Disorders | TL1A inhibitors | Absci Corp. | Absci Corp. | Preclinical | - | - | - | - | - | - | - | - | - | ABS-101 (Absci) | - | - | detail > | |
| HXN-1003 | HXN-1003 | Bispecific antibody | Immune System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases | IL-23 inhibitors TL1A inhibitors | Huashen Zhiyao Technology (Beijing) Co., Ltd. | Huashen Zhiyao Technology (Beijing) Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | HXN-1003 | - | - | detail > | |
| ESN-T | ESN-T | Small molecule drug | Other Diseases | TL1A inhibitors | Enveda Therapeutics, Inc. | Enveda Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | ESN-T | - | - | detail > | |
| ES-303 | ES-303 | Bispecific antibody | Immune System Diseases | TL1A inhibitors | Elpiscience Biopharma Ltd. | Elpiscience Biopharma Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | ES-303 | - | - | detail > |
Total 51 data
1
2
3
4
5
6
